抗击Clostridioides difficile感染:当前使用的药物
Min Quan1, Xiaoxia Zhang1, Qingqing Fang1
1Center for Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
International journal of antimicrobial agents
|May 11, 2024
概括
艰难菌感染 (CDI) 是一个主要的健康威胁,治疗方法有限. 本综述涵盖了当前和新兴疗法,包括新药和预防策略,以应对这一紧迫问题.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 困难菌感染 (CDI) 是全球紧急的健康威胁,导致严重的腹和频繁的复发.
- 目前的治疗方法,如菲达克索米辛,万科米辛和便微生物群移植有局限性.
- 治疗选择有限,需要探索新的抗CDI策略.
研究的目的:
- 为了提供对现有和正在研究的Clostridioides difficile感染 (CDI) 药物的全面概述.
- 总结新上市的药物和正在开发中的产品,用于CDI治疗和预防.
- 引导临床医生进行适当的CDI管理,并鼓励进一步的研究.
主要方法:
- 这篇叙事综述综合了有关当前和正在开发的抗CDI疗法的信息.
- 它检查了治疗活跃CDI,预防复发和初级预防的药物.
- 该审查包括临床前和临床开发阶段的药物.
主要成果:
- 已建立的治疗方法包括用于CDI的fidaxomicin和vancomycin,以及用于预防复发的bezlotoxumab.
- 许多新型治疗药物正在研究中,包括抗菌药物,预防药物和疫苗.
- 临床前研究探讨了潜在的CDI控制的菌体和特定抑制剂等药物.
结论:
- CDI治疗的格局正在演变,有前途的新药物和预防策略正在出现.
- 持续的研究和开发对于解决管理CDI及其复发的未满足需求至关重要.
- 临床医生可以从这篇评论中受益,以了解CDI的最新治疗进展.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
117
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
117
01:21Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
01:29Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126